416 related articles for article (PubMed ID: 16901656)
1. The first international meeting on V617F JAK2 mutation and its relevance in Philadelphia-negative myeloproliferative disorders.
Kiladjian JJ; Casadevall N; Vainchenker W; Fenaux P
Pathol Biol (Paris); 2007 Mar; 55(2):85-7. PubMed ID: 16901656
[TBL] [Abstract][Full Text] [Related]
2. [Myeloproliferative diseases caused by JAK2 mutation].
Nagata K; Shimoda K
Rinsho Byori; 2009 Apr; 57(4):357-64. PubMed ID: 19489438
[TBL] [Abstract][Full Text] [Related]
3. Incidence and significance of the JAK2 V617F mutation in patients with chronic myeloproliferative disorders.
Langabeer SE; Ni Ainle F; Conneally E; Lawler M
Ir J Med Sci; 2007; 176(2):105-9. PubMed ID: 17440677
[TBL] [Abstract][Full Text] [Related]
4. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
5. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
6. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
[TBL] [Abstract][Full Text] [Related]
7. The gain-of-function JAK2 V617F mutation shifts the phenotype of essential thrombocythemia and chronic idiopathic myelofibrosis to more "erythremic" and less "thrombocythemic": a molecular, histologic, and clinical study.
Rudzki Z; Sacha T; Stój A; Czekalska S; Wójcik M; Skotnicki AB; Grabowska B; Zduńczyk A; Okoń K; Stachura J
Int J Hematol; 2007 Aug; 86(2):130-6. PubMed ID: 17875526
[TBL] [Abstract][Full Text] [Related]
8. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
9. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
[TBL] [Abstract][Full Text] [Related]
10. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
[TBL] [Abstract][Full Text] [Related]
11. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the JAK2-V617F gene mutation in Turkish patients with essential thrombocythemia and polycythemia vera.
Karkucak M; Yakut T; Ozkocaman V; Ozkalemkas F; Ali R; Bayram M; Gorukmez O; Ocakoglu G
Mol Biol Rep; 2012 Sep; 39(9):8663-7. PubMed ID: 22722988
[TBL] [Abstract][Full Text] [Related]
13. The incidence of JAK2 V617F mutation in bcr/abl-negative chronic myeloproliferative disorders: assessment by two different detection methods.
Lucia E; Martino B; Mammi C; Vigna E; Mazzone C; Gentile M; Qualtieri G; Bisconte MG; Naccarato M; Gentile C; Laganà C; Romeo F; Neri A; Nobile F; Morabito F
Leuk Lymphoma; 2008 Oct; 49(10):1907-15. PubMed ID: 18720212
[TBL] [Abstract][Full Text] [Related]
14. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
Hoermann G; Cerny-Reiterer S; Herrmann H; Blatt K; Bilban M; Gisslinger H; Gisslinger B; Müllauer L; Kralovics R; Mannhalter C; Valent P; Mayerhofer M
FASEB J; 2012 Feb; 26(2):894-906. PubMed ID: 22051730
[TBL] [Abstract][Full Text] [Related]
15. Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers.
Hussein K; Bock O; Kreipe H
Pathobiology; 2007; 74(2):72-80. PubMed ID: 17587878
[TBL] [Abstract][Full Text] [Related]
16. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
[TBL] [Abstract][Full Text] [Related]
17. Association between thromboembolic events and the JAK2 V617F mutation in myeloproliferative neoplasms.
Takata Y; Seki R; Kanajii T; Nohara M; Koteda S; Kawaguchi K; Nomura K; Nakamura T; Morishige S; Oku E; Osaki K; Hashiguchi E; Mouri F; Yoshimoto K; Nagafuji K; Okamura T
Kurume Med J; 2014; 60(3-4):89-97. PubMed ID: 24858412
[TBL] [Abstract][Full Text] [Related]
18. Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice.
Marty C; Lacout C; Martin A; Hasan S; Jacquot S; Birling MC; Vainchenker W; Villeval JL
Blood; 2010 Aug; 116(5):783-7. PubMed ID: 20472827
[TBL] [Abstract][Full Text] [Related]
19. JAK2, the JAK2 V617F mutant and cytokine receptors.
Staerk J; Kallin A; Royer Y; Diaconu CC; Dusa A; Demoulin JB; Vainchenker W; Constantinescu SN
Pathol Biol (Paris); 2007 Mar; 55(2):88-91. PubMed ID: 16904848
[TBL] [Abstract][Full Text] [Related]
20. Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens.
Moliterno AR; Williams DM; Rogers O; Isaacs MA; Spivak JL
Exp Hematol; 2008 Nov; 36(11):1480-6. PubMed ID: 18723264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]